|
gptkbp:instanceOf
|
gptkb:antiprotozoal_drug
gptkb:phospholipid_derivative
|
|
gptkbp:approvalYear
|
2002
|
|
gptkbp:approvedBy
|
gptkb:India
|
|
gptkbp:ATCCode
|
P01CX05
|
|
gptkbp:brand
|
gptkb:Impavido
gptkb:Miltefos
|
|
gptkbp:CASNumber
|
58066-85-6
|
|
gptkbp:chemicalFormula
|
C21H46NO4P
|
|
gptkbp:contraindication
|
pregnancy
|
|
gptkbp:discoveredBy
|
gptkb:Asta_Medica
|
|
gptkbp:hasSMILES
|
CCCCCCCCCCCCCCCCP(=O)(OCC[N+](C)(C)C)O
|
|
gptkbp:KEGGID
|
gptkb:D02141
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
disrupts cell membrane of protozoa
|
|
gptkbp:meltingPoint
|
86-88°C
|
|
gptkbp:molecularWeight
|
407.6 g/mol
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201217
gptkb:DB09031
3599
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
abdominal pain
teratogenicity
|
|
gptkbp:UNII
|
1LQA4OC4SY
|
|
gptkbp:usedFor
|
gptkb:leishmaniasis
gptkb:visceral_leishmaniasis
amoebic meningoencephalitis
|
|
gptkbp:bfsParent
|
gptkb:Leishmania_donovani
gptkb:Leishmaniasis
|
|
gptkbp:bfsLayer
|
5
|
|
http://www.w3.org/2000/01/rdf-schema#label
|
miltefosine
|